Preview

Кардиология

Расширенный поиск

Актуальные вопросы подбора антикоагулянтной терапии для длительной профилактики тромбоэмболических осложнений

https://doi.org/10.18087/cardio.2017.10021

Полный текст:

Аннотация

В статье представлены актуальные проблемы подбора антикоагулянтной терапии для длительной профилактики тромбоэмболических осложнений у амбулаторного пациента с фибрилляцией предсердий, хронической сердечной недостаточностью и хронической болезнью почек.

Об авторах

Т. В. Павлова
ФГБОУ ВО «Самарский государственный медицинский университет»
Россия


И. Л. Воронова
ФГБОУ ВО «Самарский государственный медицинский университет»
Россия


Д. В. Дупляков
ФГБОУ ВО «Самарский государственный медицинский университет»; ГБУЗ «Самарский областной клинический кардиологический диспансер» Минздрава РФ
Россия


Список литературы

1. Chugh S.S., Havmoeller R., Narayanan K. et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2014;129:837-847.

2. Dzau V., Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J. 1991;121(4 Pt 1):1244-1263.

3. Olesen J.B., Lip G.Y., Kamper A.L. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N. Engl J. Med 2012;367(7):625-635.

4. Benjamin E.J., Levy D., Vaziri S.M. et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994;271(11):840-844.

5. Cleland J.G., Chattopadhyay S., Khand A. et al. Prevalence and incidence of arrhythmias and sudden death in heart failure. Heart Fail Rev 2002;7(3):229-242.

6. Bos M.J., Koudstaal P.J., Hofman A., Breteler M.M. Decreased glomerular filtration rate is a risk factor for hemorrhagic but not for ischemic stroke: the Rotterdam Study. Stroke 2007;38:3127-3132.

7. Sarnak M.J., Levey A.S., Schoolwerth A.C. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003;42:1050-1065.

8. Watanabe H., Watanabe T., Sasaki S. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. Am Heart J. 2009;158(4):629-636.

9. Zimmerman D., Sood M.M., Rigatto C. et al. Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. Nephrol Dial Transplant 2012;27:3816-3822.

10. Ronco C., McCullough P., Anker S. Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative. Eur Heart J. 2010;31:703-711.

11. Iguchi Y., Kimura K., Kobayashi K. Relation of atrial fibrillation to glomerular filtration rate. AmJ Cardiol 2008;102(8):1056-1059.

12. Go A.S., Fang M.C., Udaltsova N. et al.; ATRIA Study Investigators. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 2009;119:1363-1369.

13. Olesen J.B., Lip G.Y., Kamper A.L. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N. EnglJ Med 2012;367(7): 625-635.

14. ESC Guidelines. Management of atrial fibrillation. Eur Heart J. 2016;37(38):2893-2962.

15. Терещенко С. Н., Романова Н. В., Жиров И. В. и др. Российский регистр больных хронической сердечной недостаточностью и фибрилляцией предсердий (РИФ-ХСН): клинико-демографические харак теристики выборки на момент включения в регистр. Журнал Сердечная недостаточность 2016;17 (6):418-426

16. Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-867.

17. Cherian T.S., Shrader P., Fonarow G.C. et al. Effect of Atrial Fibrillation on Mortality, Stroke Risk, and Quality-of-Life Scores in Patients With Heart Failure (from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF]). Am J. Cardiol 2017;119(11):1763-1769.

18. Beyer-Westendorf J., Forster K., Pannach S. et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: Results from the Dresden NOAC registry. Blood 2014;124(6):955-962.

19. Michalski F., Tittl L., Werth S. et al. Selection, management, and outcome of vitamin K. antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry. Thromb Haemost 2015;114(5):1076-1084.

20. Coleman C.I., Roberts M.S., Sobieraj D.M. et al. Curr Med Res Opin 2012;28(5):669-680.

21. van Diepen S., Hellkamp A.S., Patel M.R. Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF. Circ Heart Fail 2013;6(4):740-747.

22. Fox K.A., Piccini J.P., Wojdyla D. et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011;32(19):2387-2394.

23. Fordyce C.B., Hellkamp A.S., Lokhnygina Y. et al. On-Treatment Outcomes in Patie3 4nts With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF. Circulation 2016;134(1):37-47.

24. Hijazi Z., Hohnloser S.H., Andersson U. et al. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time. Insights From the ARISTOTLE Randomized Clinical Trial JAMA Cardiol 2016;1(4):451-460.

25. McHorney C.A. et al., Rivaroxaban users have significantly less treatment discontinuation compared with users of other oral anticoagulants in non-valvular atrial fibrillation. American College of Cardiology Conference 2017, Washington, DC, USA, 17-19 March 2017; Poster 1252-1306.

26. Andrade J.G., Krahn A.D., Skanes A.C. et al. Values and Preferences of Physicians and Patients With Nonvalvular Atrial Fibrillation Who Receive Oral Anticoagulation Therapy for Stroke Prevention. Can J Cardiol 2016;32(6):747-753.

27. Beyer-Westendorf J., Forster K., Ebertz F. et al. Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry. Europace 2015;17(4):530-538.

28. McHorney C.A., Peterson E.D., Laliberte F. et al. Comparison of Adherence to Rivaroxaban Versus Apixaban Among Patients With Atrial Fibrillation. Clin Ther 2016;38(11):2477-2488.


Для цитирования:


Павлова Т.В., Воронова И.Л., Дупляков Д.В. Актуальные вопросы подбора антикоагулянтной терапии для длительной профилактики тромбоэмболических осложнений. Кардиология. 2017;57(8):71-79. https://doi.org/10.18087/cardio.2017.10021

For citation:


Pavlova T.V., Voronova I.L., Duplyakov D.V. Actual Issues of Choosing Anticoagulant Therapy for Long-term Prophylaxis of Thromboembolic Complications. Kardiologiia. 2017;57(8):71-79. (In Russ.) https://doi.org/10.18087/cardio.2017.10021

Просмотров: 60


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 0022-9040 (Print)
ISSN 2412-5660 (Online)